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Abstract
Drug combinations for the treatment of leishmaniasis represent a promising and challenging chemotherapeutic strategy
that has recently been implemented in different endemic areas. However, the vast majority of studies undertaken to date
have ignored the potential risk that Leishmania parasites could develop resistance to the different drugs used in such
combinations. As a result, this study was designed to elucidate the ability of Leishmania donovani to develop experimental
resistance to anti-leishmanial drug combinations. The induction of resistance to amphotericin B/miltefosine, amphotericin
B/paromomycin, amphotericin B/SbIII, miltefosine/paromomycin, and SbIII/paromomycin was determined using a step-wise
adaptation process to increasing drug concentrations. Intracellular amastigotes resistant to these drug combinations were
obtained from resistant L. donovani promastigote forms, and the thiol and ATP levels and the mitochondrial membrane
potential of the resistant lines were analysed. Resistance to drug combinations was obtained after 10 weeks and remained
in the intracellular amastigotes. Additionally, this resistance proved to be unstable. More importantly, we observed that
promastigotes/amastigotes resistant to one drug combination showed a marked cross-resistant profile to other anti-
leishmanial drugs. Additionally, the thiol levels increased in resistant lines that remained protected against the drug-induced
loss of ATP and mitochondrial membrane potential. We have therefore demonstrated that different resistance patterns can
be obtained in L. donovani depending upon the drug combinations used. Resistance to the combinations miltefosine/
paromomycin and SbIII/paromomycin is easily obtained experimentally. These results have been validated in intracellular
amastigotes, and have important relevance for ensuring the long-term efficacy of drug combinations.
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Introduction
The use of drug combinations, either in co-formulations or co-
administrations, is an established approach for the treatment of
several infectious diseases including malaria and tuberculosis [1].
This approach has also recently become a priority for other
tropical parasitic diseases, such as visceral leishmaniasis [2–6].
Leishmaniasis, a neglected tropical parasitic disease that is
prevalent in 98 countries spread across three continents, is caused
by protozoan parasites belonging to the genus Leishmania [7]. The
estimated incidence of leishmaniasis is 0.2–0.4 million cases of the
visceral form (VL) and 0.7–1.2 million cases of the cutaneous form
(CL) [7]. Although chemotherapy is the only current treatment
option for leishmaniasis, its efficacy is increasingly limited by
growing resistance to first-line drugs, especially antimonials, the
frequent side-effects associated with their use, and the high cost of
treatment [7,8]. The recommended first-line therapies for VL
include: i) pentavalent antimonials (meglumine antimoniate and
sodium stibogluconate), except in some regions in the Indian
subcontinent where there are significant areas of drug resistance
[9]; ii) the polyene antibiotic amphotericin B (AmB); iii) the
liposomal formulation AmBisome; iv) the aminoglycoside paro-
momycin (PMM); and v) the oral drug miltefosine (MLF).
Recently, the WHO [7,10], recommended to use either a single
dose of AmBisome or combinations of anti-leishmanial drugs in
order to reduce the duration and toxicity of treatment, prolong the
therapeutic life span of existing drugs and delay the emergence of
resistance.
Although recent clinical trials have highlighted the efficacy and
safety of anti-leishmanial drug combinations [4,5,10–12], addi-
tional clinical studies are needed to investigate various other
factors, such as the identification of an effective, well-tolerated and
short treatment regimen, logistical aspects, and the potential risk of
developing resistance considering that compliance in field
conditions can be low [13].
Herein we describe the selection and characterization of
experimental resistance to drug combinations in Leishmania
parasites. Our findings clearly demonstrate the acquisition of
resistance to different drug combinations in Leishmania donovani
promastigotes using a step-wise adaptation process to increasing
drug concentrations. Similarly, and perhaps importantly, we have
obtained intracellular L. donovani amastigotes that are resistant to
different drug combinations from promastigote forms resistant to
these same combinations. These results indicate different patterns
of resistance depending on the drug combinations used, with the
combination MLF/PMM selecting resistant L. donovani more
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rapidly than the combination AmB/PMM. Significantly, we have
also observed that promastigotes/amastigotes resistant to one drug
combination show a marked cross-resistance profile to other anti-
leishmanial drugs, a finding that could be of major clinical
relevance. Additionally, our results indicate that the resistant lines




Trivalent antimony (SbIII), paromomycin (PMM), amphotericin
B (AmB), paraformaldehyde, MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide], Rhodamine 123 (Rh123),
buthionine sulfoximine (BSO), FCCP (carbonyl cyanide 4-trifluor-
omethoxyphenylhydrazone), and Triton X-100 were obtained from
Sigma-Aldrich (St. Louis, MO). Miltefosine (MLF) was purchased
from Zentaris GmbH (Frankfurt am Main, Germany), and
CellTiter-Glo, CellTracker, and 49, 6-diamidino-2-phenylindole
dihydrochloride (DAPI) were purchased from Invitrogen. L-
glutamine and penicillin/streptomycin were obtained from Gibco.
All chemicals were of the highest quality available.
Leishmania culture conditions
The L. donovani promastigotes (MHOM/ET/67/HU3) and
derivative lines used in this study were grown at 28uC in RPMI
1640-modified medium (Invitrogen) supplemented with 20% or
10% heat-inactivated fetal bovine serum (HIFBS, Invitrogen). For
thiol assays, they were grown in M-199 medium (Gibco)
supplemented with 10% HIFBS.
Development of drug-resistant Leishmania
promastigotes
The resistant lines were obtained following a previously
described step-wise adaptation process [14,15]. This process
started with drug pressure in the wild-type (WT) L. donovani line
at a concentration below the drug EC50 (the concentration of the
drug required to inhibit parasite growth by 50%), gradually
increasing the drug pressure over 10 weeks. After this period, the
resistant lines were maintained for eight further weeks at the final
drug concentration. The drug combination resistant lines gener-
ated, based on WHO recommendations [7], were AmB+MLF
(AM), AmB+PMM (AP), AmB+SbIII (the antimonial active form;
AS), MLF+PMM (MP) and SbIII+PMM (SP). Singly resistant lines
named A, M, P, and S were obtained in a similar manner. All
resistant lines were maintained in the continuous presence of
drugs. Resistance stability was checked at one and four months
after removal from drug pressure. The EC50, resistance index
(EC50 ratio for resistant and WT parasites), and cross-resistance
profile were determined for each line using an MTT colorimetric
assay after incubation for 72 h at 28uC in the presence of
increasing concentrations of the drug, as described previously [16].
Animals
Six-week-old male BALB/c mice were purchased from Charles
River Breeding Laboratories and maintained in the Animal
Facility Service of our Institute under pathogen-free conditions.
They were fed a regular rodent diet and given drinking water ad
libitum. These mice were used to collect primary peritoneal
macrophages.
Ethics statement
All experiments were performed according to National/EU
guidelines regarding the care and use of laboratory animals in
research. Approval for these studies was obtained from the Ethics
Committee of the Spanish National Research Council (CSIC file
CEA-213-1-11).
Drug sensitivity in intracellular Leishmania amastigotes
Mouse peritoneal macrophages were obtained as described
previously [17] and plated at a density of 16105 macrophages/
well in RPMI 1640 medium supplemented with 10% HIFBS,
2 mM glutamate, penicillin (100 U/mL) and streptomycin
(100 mg/mL) in 24-well tissue culture chamber slides. Late-stage
promastigotes from WT and resistant lines were used to infect
macrophages at a macrophage/parasite ratio of 1:10. Eight hours
after infection at 35uC in an atmosphere containing 5% CO2,
extracellular parasites were removed by washing with serum-free
medium. Infected macrophage cultures were maintained in RPMI
1640 medium plus 10% HIFBS at 37uC with 5% CO2 at different
drug concentrations. After 72 h, macrophages were fixed for
30 min at 4uC with 2.5% paraformaldehyde in phosphate-
buffered saline (PBS; 1.2 mM KH2PO4, 8.1 mM Na2HPO4,
130 mM NaCl, and 2.6 mM KCl adjusted to pH 7), and
permeabilized with 0.1% Triton X-100 in PBS for 30 min.
Intracellular parasites were detected by nuclear staining with
Prolong Gold antifade reagent plus DAPI. Drug activity was
determined from the percentage of infected cells and the number
of amastigotes per cell in drug-treated versus non-treated cultures
[17].
Determination of intracellular levels of non-protein thiols
The levels of non-protein thiols were measured by flow
cytometry using CellTracker, as described previously [18].
Parasites (107 promastigotes/mL), grown in M199 medium plus
10% HIFBS were washed twice with PBS and incubated with
2 mM CellTracker for 15 min at 37uC. They were then washed
again with PBS and analysed by flow cytometry in a FACScan
Author Summary
Leishmania is a protozoan parasite that infects human
macrophages to produce the neglected tropical disease
known as leishmaniasis. Chemotherapy is currently the
only treatment option for leishmaniasis. First-line therapies
include pentavalent antimonials, except in some regions in
the Indian subcontinent, the liposomal formulation of
amphotericin B, miltefosine and paromomycin. The WHO
has recently recommended a combined therapy in order
to extend the life expectancy of these compounds.
However, resistance could be induced in Leishmania if
this approach is not applied in a controlled and regulated
way, thus resulting in a rapid loss of efficacy of not one but
two therapeutic options. In light of this, we have designed
relevant experimental studies in order to determine
whether Leishmania parasites are able to develop resis-
tance to the different potential anti-leishmanial drug
combinations that will be used in the near future. The
results obtained could help us to predict the success of
drug combination therapy. Experimental resistance of
Leishmania donovani promastigotes to drug combinations
was obtained after 10 weeks and remained in the
intracellular amastigotes. We therefore conclude that L.
donovani can easily develop resistance to drug combina-
tions mainly miltefosine/paromomycin and SbIII/paromo-
mycin. These results have been validated in intracellular
amastigotes and are of considerable interest for future
prediction of the success of drug combination therapy.
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flow cytometer (Becton-Dickinson, San Jose, CA) equipped with
an argon laser operating at 488 nm. Fluorescence emission
between 515 and 545 nm was quantified using the Cell Quest
software. Non-protein thiol-depleted parasites obtained after
incubation with 3 mM BSO (a c-glutamylcysteine synthetase
inhibitor) for 48 h at 28uC were used as controls.
ATP measurements
ATP was measured using a CellTiter-Glo luminescence assay,
which generates a luminescent signal proportional to the amount of
ATP present, as described previously [19]. Promastigotes (46106/
mL) were incubated at 28uC in RPMI plus 20% HIFBS containing
0.2 mM AmB or 25 mM MLF for 3 h, or 2 mM SbIII for 8 h. The
drug concentration and incubation time were selected by monitor-
ing parasite viability under a microscope. A 25-mL aliquot of
parasites was then transferred to a 96-well plate, mixed with the
same volume of CellTiter-Glo, and incubated in the dark for
10 min. The resulting bioluminescence was measured using an
Infinite F200 microplate reader (Tecan Austria GmbH, Austria).
Measurement of mitochondrial membrane potential
(DYm)
DYm was measured by flow cytometry using Rh123 accumu-
lation, as described previously [20]. The parasites (46106
promastigotes/mL) were incubated with the drugs as described
above. 0.5 mM Rh123 was then added and the parasites incubated
for a further 10 min. They were then washed twice, resuspended
in PBS and analysed by flow cytometry in a FACScan flow
cytometer (Becton-Dickinson, San Jose, CA) equipped with an
argon laser operating at 488 nm. Fluorescence emission between
515 and 545 nm was quantified using the Cell Quest software.
Parasites fully depolarized by incubation in 10 mM FCCP for
10 min at 28uC were used as controls.
Statistical analysis
Statistical comparisons between groups were performed using
Student’s t-test. Differences were considered significant at a level of
p,0.05.
Results
Generation of singly and drug combination resistant
promastigote lines
The resistant lines were selected in vitro in L. donovani promasti-
gotes by a stepwise adaptation process, with drug concentrations
starting below the EC50 values and gradually increasing, over 10
weeks (equivalent to 90 generations), to a maximum concentration
of 0.1, 8, 20 and 80 mM for AmB, MLF, PMM and SbIII,
respectively. Resistance to single drugs and to double drug
combinations was induced. The singly AmB-resistant line (A) and
the lines resistant to the combination of AmB with MLF (AM),
PMM (AP) or SbIII (AS) showed similar EC50 values for AmB of
0.14 mM, a value two-fold higher than for the WT line (Table 1). In
contrast, the singly MLF-resistant line (M) and the lines resistant to
the combination of MLF with AmB (AM) or PMM (MP) showed
EC50 values for MLF 1.81, 3.10, and 4.43-fold higher than for the
WT line, respectively (Table 1). Likewise, the singly PMM-resistant
line (P) and the lines resistant to combinations with AmB (AP), MLF
(MP) or SbIII (SP), showed EC50 values for PMM11.02, 2.12, 14.25,
and 18.35-fold higher than for the WT line, respectively (Table 1).
Finally, the line resistant to SbIII alone (S) and the lines resistant to
SbIII in combination with AmB (AS) or PMM (SP) showed EC50
values for SbIII that were 3.04, 2.05, and 2.18-fold higher than for
the WT line, respectively (Table 1). All the resistant lines showed a
similar growth rate, morphology, motility and macrophage
infectivity to the WT line (data not shown).
Maintenance of drug resistance in intracellular
amastigotes
We undertook additional experiments to determine whether the
resistance to single drugs and drug combinations shown by the
promastigote forms was maintained in intracellular amastigotes
obtained after infection of mouse peritoneal macrophages (Table 2).
The results indicated that the resistance indices to drugs in the
different resistant intracellular amastigote lines were maintained
and were very similar to those observed in their promastigote
counterparts (Tables 1 and 2). The exception was the S-resistant
Table 1. Drugs sensitivity profile in L. donovani promastigote lines.
Lines Drugs EC50 (mM)-Resistance Index
AmB MLF PMM SbIII
WT 0.0760.01 5.8460.43 12.0961.76 87.3365.72
A 0.1460.04* (2.0060.57) 5.2860.58 (0.9060.16) 19.6761.30**** (1.6360.34) 74.3864.98* (0.8560.12)
M 0.0760.03 (1.0060.56) 10.5661.06****,a (1.8160.31) 6.9360.80 (0.5760.15) 92.2367.09 (1.0660.16)
P 0.0760.02 (1.0060.42) 4.9860.38* (0.8560.12) 133.29612.36****,b,c (11.0261.63) 138.15615.54**** (1.5860.29)
S 0.0760.02 (1.0060.42) 4.2560.44*** (0.7360.13) 109.3462.94**** (9.0460.85) 266.07610.12****,d,e (3.0460.32)
AM 0.1460.04* (2.0060.86) 18.0361.07**** (3.0960.40) 19.3563.67* (1.6060.53) 108.9764.67**** (1.2560.14)
AP 0.1460.04* (2.0060.86) 10.8661.67**** (1.8660.42) 25.6762.26**** (2.1260.40) 96.6965.60 (1.1160.14)
AS 0.1460.04* (2.0060.86) 5.7960.40 (0.9960.13) 22.8262.92**** (1.8960.51) 178.8865.91**** (2.0560.49)
MP 0.0760.03 (1.0060.56) 25.9061.74**** (4.4360.61) 172.2763.52**** (14.2561.35) 74.5963.85** (0.8560.10)
SP 0.0760.02 (1.0060.42) 4.6161.02 (0.7960.23) 221.88630.15**** (18.3562.15) 190.57620.96**** (2.1860.39)
Promastigote forms of L. donovani lines: wild-type (WT) and resistant lines to AmB (A), MLF (M), PMM (P), SbIII (S), AmB+MLF (AM), AmB+PMM (AP), AmB+SbIII (AS),
MLF+PMM (MP), and SbIII+PMM (SP), were grown as described in Materials and Methods section for 72 h at 28uC in the presence of increasing concentrations of drugs.
Cell viability was determined using an MTT-based assay. Resistance indexes, between parentheses, were calculated by dividing the EC50 for each resistant line by that for
WT line. Data are means of EC50 or resistance indexes values 6 SD from three independent experiments. Significant differences versus the WT were determined using
Student’s t-test (*: p,0.05; **: p,0.01; ***: p,0.005; ****: p,0.001) and for comparison of singly versus doubly-resistant lines (a: p,0.001 M vs. AM or MP; b: p,0.05 P vs.
MP or SP; c: p,0.001 P vs. AP; d: p,0.05 S vs. SP; e: p,0.005 S vs. AS).
doi:10.1371/journal.pntd.0001974.t001
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line, which showed a significantly higher resistance index to SbIII
(12-fold, Table 2) than that observed for the promastigote form (3-
fold, Table 1). The higher resistance index for PMM in the singly P-
resistant line (11-fold) and in the MP-(11- and 14-fold for
intracellular amastigotes and promastigotes, respectively) and SP-
resistant lines (16- and 18-fold for intracellular amastigotes and
promastigotes, respectively) it worthy of note. Furthermore, a
comparison of AP with P, and AS or SP with S, shows that the
doubly resistant lines exhibit lower EC50 values for PMM or Sb
III
than their singly resistant counterparts. In contrast, the SP line
exhibits a higher EC50 value for PMM than the P line (Table 2).
Stability of resistance to drug combinations
The resistant phenotypes were stable in a drug-free medium for
1 month in the singly A-resistant and AM, AP, and AS doubly-
resistant lines for AmB. In contrast, the remaining resistances were
unstable, although the EC50 values were higher than for the WT
line, except for the M and AP lines, which lost resistance against
MLF and PMM, respectively (Figure 1). After culture for four
months in a drug-free medium, all lines lost their resistance levels
either completely or partially, except the AP line, which
maintained a similar initial resistance level for AmB (Figure 1).
These findings suggest that the resistance phenotype of the
induced drug combination resistance is unstable.
Cross-resistance profile to drugs in resistant lines
We investigated the cross-resistance profile of the promastigote
and intracellular amastigote forms of each resistant line to different
anti-leishmanial drugs (Tables 1 and 2). Both the A- and S-
resistant lines showed a significant cross-resistance profile to PMM
(Table 1), and the P-resistant line showed resistance to SbIII
(Table 1). However, the M and P lines only showed resistance to
SbIII in their intracellular amastigote forms (Table 2). In the case
of drug combination resistant lines, we found that the AP-resistant
line showed significant cross-resistance to MLF in both its
promastigote and intracellular amastigote forms. Similarly, the
AS-resistant promastigote line shows cross-resistance to PMM, and
the AM-resistant promastigote line shows cross-resistance to PMM
and SbIII (Tables 1 and 2). However, the MP and SP lines showed
no cross-resistance to other anti-leishmanial drugs as either
promastigotes or intracellular amastigotes (Tables 1 and 2). Our
results concerning the stability of the cross-resistance in resistant
lines maintained without drug pressure for one month showed that
all lines maintained their resistance, except the AM line, which lost
its cross-resistance to SbIII (Figure 2).
Intracellular thiol levels in resistant lines
An increase in thiol levels has been considered to be one of the
main detoxification mechanisms observed in lines selected for
resistance to SbIII [21]. In light of this, we determined the total
intracellular non-protein thiol content in the different resistant
promastigote lines using CellTracker. The results of this study
showed significantly higher thiol levels in the resistant lines than in
the WT line, except for the M and S lines (Figure 3). The highest
thiol values were found in the MP and SP lines. As expected, a
drastic decrease in thiol content was observed in all lines after
incubation with BSO (Figure 3).
The effect of anti-leishmanial drugs on ATP synthesis in
drug-resistant lines
We assessed the ATP levels in the presence of AmB, MLF and
SbIII, which are known to induce an apoptotic-like process
associated with ATP depletion in Leishmania [22]. PMM was not
assessed as this drug kills the parasites by a different mechanism
[22–24]. The WT parasites exhibited a significant decrease in total
ATP levels after treatment with AmB, MLF or SbIII, with the
former showing the highest decrease (Figure 4A). The lines
resistant to single and drug combinations remained protected or
were more tolerant to ATP loss (Figure 4A), with the AS-resistant
line in particular showing a very small decrease in ATP levels after
treatment with AmB or SbIII. A similarly small decrease in ATP
levels was also observed after treatment of the M- and MP-
resistant lines with MLF, and the S-resistant line with SbIII
(Figure 4A). Additionally, we observed that the M- and S-resistant
lines presented significantly higher basal ATP levels without drug
pressure (Figure 4A), thus suggesting that these resistant lines have
Table 2. Drugs sensitivity profile in L. donovani intracellular amastigote lines.
Lines Drugs EC50 (mM)-Resistance Index
AmB MLF PMM SbIII
WT 0.02760.002 2.1860.43 3.9360.60 3.6660.14
A 0.05760.003****,a (2.11060.270) 2.0360.33 (0.9360.13) 4.4360.45 (1.1360.28) 2.3860.19*** (0.6560.07)
M 0.02860.002 (1.03760.145) 5.1260.51*** (2.3560.69) 5.2660.35 (1.3460.29) 5.1160.46* (1.4060.18)
P 0.02660.003 (0.96360.180) 1.9860.23 (0.9160.28) 41.4563.78****,b,c (10.5561.57) 4.6660.35* (1.2760.14)
S 0.02460.002 (0.88960.140) 2.0860.17 (0.9560.26) 4.3660.53 (1.1160.30) 44.4764.23****,d,e (12.1560.92)
AM 0.06460.002**** (2.37060.251) 4.6260.39** (2.1260.87) 3.4560.49 (0.8860.26) 3.3660.23 (0.9260.09)
AP 0.05860.003**** (2.14860.273) 3.9860.41* (1.8360.24) 7.1060.62**** (1.8160.43) 3.9860.29 (1.0960.09)
AS 0.04260.003** (1.55660.342) 3.4660.54 (1.5960.16) 3.9360.51 (1.0060.28) 6.6160.57*** (1.8160.22)
MP 0.03660.004 (1.33360.256) 7.0961.07*** (3.2561.31) 41.5863.44**** (10.5861.49) 3.4860.27 (0.9560.14)
SP 0.02660.004 (0.96360.226) 2.4660.47 (1.1360.23) 64.4865.34**** (16.4161.84) 14.0562.04*** (3.8460.69)
Intracellular amastigote L. donovani lines were obtained after infection of mouse peritoneal macrophages with the different promastigote resistant lines as described in
Material and Methods section. After 72 h, drug activity was determined from the percentage of infected cells and the number of amastigotes by cells in drug-treated
cultures versus non-treated cultures. Resistance indexes, between parentheses, were determined as previously described in Table 1. Data are means of EC50 or resistance
indexes values 6 SD from three independent experiments. Significant differences versus the WT were determined using Student’s t-test (*: p,0.05; **: p,0.01;
***: p,0.005; ****: p,0.001) and for comparison of singly versus doubly-resistant lines (a: p,0.05 A vs. AS; b: p,0.05 P vs. SP; c: p,0.001 P vs. AP; d: p,0.005 S vs. SP;
e: p,0.001 S vs. AS).
doi:10.1371/journal.pntd.0001974.t002
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developed, amongst other resistance mechanisms, an increase in
ATP levels. In contrast, the AM- and AP-resistant lines presented
significantly lower basal ATP levels (Figure 4A).
Tolerance to drug-induced depolarization of DYm in
drug-resistant lines
DYm is essential to mitochondrial ATP synthesis and changes
to it are one of the markers for apoptosis induced by exposure to
AmB, MLF and SbIII (but not exposure to PMM) [22].
Furthermore, mitochondrial oxidative phosphorylation in Leish-
mania accounts for most of the ATP expenditure of Leishmania
parasites [25]. As a result, we tested the DYm of WT and the
various resistant lines by measuring Rh123 accumulation
(Figure 4B). WT parasites incubated with AmB, MLF or SbIII
showed a significant decrease in Rh123 accumulation (7.7-, 2.6-
and 1.4-fold, respectively). These values (except for that for SbIII)
were even lower than those obtained upon incubation of parasites
with the control uncoupling reagent FCCP (Figure 4B). Except for
the M-resistant line, the untreated resistant lines showed a
significantly lower accumulation of Rh123; however, after
treatment with the different anti-leishmanial drugs, the resistant
lines showed a lower reduction ratio of Rh123 accumulation than
the WT line (Figure 4B). Consequently, the resistant parasites
remain protected against the oxidative stress induced by treatment
with the anti-leishmanial drugs AmB, MLF and SbIII.
Discussion
Drug combinations for the treatment of leishmaniasis represent
a promising and challenging chemotherapeutic strategy that has
recently been implemented in different endemic areas. This
approach has several advantages over single-drug therapies,
including shortening of the treatment period and reduction of
Figure 1. Stability of resistance to drugs in L. donovani promastigote lines. (A) The stability of resistance with respect to the initial EC50
(black columns) is determined at 1 (gray columns) and 4 months (white columns) after removal of the drug pressure. The results shown are the
average of three independent experiments 6 SD. Significant differences versus the initial EC50 were determined using Student’s t-test (*: p,0.05;
**: p,0.01; ***: p,0.005; ****: p,0.001). (B) Results from panel A expressed in terms of the resistance index. The horizontal black line represents a
resistance index of 1 equivalent to a completely loss of resistance. a: line that lose resistance after 1 month in a drug-free medium; b: line that maintain
similar initial resistance levels after 4 months in a drug-free medium.
doi:10.1371/journal.pntd.0001974.g001
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the probability of selecting drug-resistant parasites. However, this
approach must be used with care given to the possibility that, if not
applied in a controlled and regulated way, resistance could be
induced in Leishmania, thus resulting in a rapid loss of efficacy of
not one but two therapeutic options [13]. It is therefore important
to design relevant experimental studies in order to determine
whether Leishmania parasites are able to develop resistance to the
different potential anti-leishmanial drug combinations that are
likely to be used in the near future. The results obtained from such
experimental studies could help to predict the likely success of drug
combination therapy.
There is still a great deal of debate concerning the clinical
relevance of findings in promastigotes since this is not the stage
that will eventually become exposed to the drug. It has recently
been shown that differences can be obtained during the
experimental induction of resistance to PMM using promastigotes
and intracellular amastigotes depending on the resistance-selection
protocol [26]. The methodology and technical difficulties required
in inducing resistance to drug combinations justify the use of
promastigote forms in this manuscript. However, experiments
using intracellular amastigotes derived from resistant promasti-
gotes could be useful when considering future recommendations
Figure 2. Stability of cross-resistance to drugs in L. donovani promastigote lines. (A) The stability of cross-resistance at 1 month after
removal of drug pressure (gray columns), relative to initial EC50 (black columns), was determined. The results are the average of three independent
experiments 6 SD. Significant differences versus the initial EC50 were determined using Student’s t-test (*: p,0.005). (B) Results from panel A
expressed in terms of resistance index. The horizontal black line represents a resistance index of 1 equivalent to a completely loss of resistance. a: line
that lose resistance after 1 month in a drug-free medium.
doi:10.1371/journal.pntd.0001974.g002
Figure 3. Thiol levels in L. donovani promastigote lines. Log-phase promastigotes from WT and resistant lines were labelled with 2 mM
CellTracker (black columns), and fluorescence was analyzed as described in the Materials and Methods section. Promastigotes were depleted of thiols
by treatment with 3 mM BSO (a c-glutamylcysteine synthetase inhibitor) for 48 h at 28uC (white columns). The results are the average of three
independent experiments 6 SD. All lines show significant differences with respect to WT (*: p,0.001) and when comparing singly versus doubly-
resistant lines using Student’s t-test (a: p,0.05 A vs. AS; b: p,0.005 A vs. AP; c: p,0.001 A vs. AM; d: p,0.001 M vs. AM or MP; e: p,0.05 P vs. AP;
f: p,0.001 P vs. MP or SP; g: p,0.001 S vs. AS or SP). The black line indicates the threshold at which the thiol levels have been modified with respect
to WT.
doi:10.1371/journal.pntd.0001974.g003
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for optimal drug combinations to combat different Leishmania
species.
Studies in clinically resistant isolates, where the mechanisms of
resistance involve multi-factorial events that contribute to the
tolerance to chemotherapeutic agents in Leishmania, are somewhat
more complex [27,28]. In this paper, we have induced experi-
mental resistance to the drug combinations AM, AP, AS, MP and
SP in L. donovani (MHOM/ET/67/HU3, also known as LV9 or
L82). The sensitivity values of the parental L. donovani strain to the
different anti-leishmanial drugs used were similar to, or even lower
than, the published data for this and other L. donovani strains
[11,26,29–31]. It is important to point out that this is the first
description of an experimental induction of resistance to a
combination of different anti-leishmanial drugs. Consequently,
the conditions and times required for the induction of resistance
can not be compared to the previously described induction of
resistance to single anti-leishmanial drugs. Additionally, the single-
drug resistance studies in L. donovani described by different groups,
obtained higher levels of resistance after increasing the drug
pressure and exposure times. Thus, an approximately 14-fold
resistance has been obtained for MLF resistance [32], an
approximately 5- to11-fold resistance for PMM, depending on
the L. donovani strain used [26], and an approximately 20-fold
resistance for AmB [31]. Moreover, it is important to note that, in
clinical isolates resistant to sodium stibogluconate, an up to 41-fold
higher tolerance to SbIII has been observed with respect to the
susceptible clones of promastigote forms in the stationary growth
phase [27].
In summary, the results of this study show that L. donovani can
easily develop resistance to the drug combinations MLF/PMM
and SbIII/PMM, with higher resistance indices than those found
for AmB/MLF, AmB/PMM or AmB/SbIII. These results have
Figure 4. Effect of anti-leishmanial drugs on ATP synthesis and DYm in resistant L. donovani promastigote lines. (A) ATP levels were
measured using CellTiter-Glo. (B) DYm was measured by determining the accumulation of Rh123 (0.5 mM) in WT and resistant lines. In both cases,
promastigote log-phase cultures were left untreated (controls, black columns) or exposed to 0.2 mM AmB (white columns), 25 mM MLF (oblique lines
columns) for 3 h, 2 mM SbIII (gray columns) for 8 h, or 10 mM FCCP as a depolarization control (light gray columns) for 10 min. Measurements are
expressed in arbitrary luminescence (panel A) or fluorescence (panel B) units 6 SD from three independent experiments and show significant
differences (a: p,0.05; b: p,0.01; c: p,0.005; d: p,0.001) when comparing the corresponding control values for each line with itself after treatment. A
comparison of the different untreated lines with untreated WT lines also shows significant differences (*: p,0.05; **: p,0.005; ***: p,0.001).
doi:10.1371/journal.pntd.0001974.g004
Resistance to Drug Combinations in Leishmania
PLOS Neglected Tropical Diseases | www.plosntds.org 7 December 2012 | Volume 6 | Issue 12 | e1974
been validated in intracellular amastigotes and are of considerable
interest for future applications. Experimental resistance of L.
donovani to the drug combination MLF/PMM, a combination that
could, in theory, have advantages over other drug combinations as
regards future use, is easily achieved. Similarly, the experimental
studies described herein confirm how the ease with which
experimental resistance to SbIII/PMM is induced in Leishmania.
These studies should therefore be taken into account when it
comes to future recommendations for their use in endemic areas,
especially as the SbIII/PMM combination appears to be effective
against VL (in East Africa) and has the additional advantage of low
cost [7]. Consequently, further research into combination
regimens when given for a short period and at lower total dose
are required.
We have also confirmed that Leishmania-resistant parasites
develop an increase in cellular thiol redox metabolism as a drug-
detoxification mechanism to protect against drug-induced loss of
ATP and mitochondrial membrane potential. As described
previously, the anti-leishmanial drugs AmB, MLF and SbIII (but
not PMM) induce a significant decrease in the mitochondrial
membrane potential, thus leading to a bioenergetic collapse of the
parasite and drug-induced cell-death [22]. A link between the
mode of killing of drugs against Leishmania infantum (such as AmB,
MLF and Sb, which share a similar mode of killing), and the
tolerance towards cell death induced by their respective anti-
leishmanial drugs, has been described previously [22]. Although,
in contrast to PMM, this was thought to facilitate the emergence of
multidrug resistance, similar findings were not observed under our
experimental conditions. Instead, our results show a significant
cross-resistance profile to PMM in the AM- and AS-resistant lines
and to MLF in the AP-resistant line. Conversely, the AP-resistant
intracellular amastigote line acquired cross-resistance to MLF. A
similar absence of a link between cross-resistance to drugs with
similar mechanism-of-death pathways was observed in the singly
A- and S-resistant promastigote lines, with a cross-resistance to
PMM, and in the P-resistant line, with resistance to SbIII. The
absence of any such correlation could be explained by taking into
account that different Leishmania species present different drug
susceptibilities and different abilities to respond to drug pressure.
In light of the characteristics of this infectious disease and the
existence of different Leishmania species, with their different drug
susceptibilities, it is possible that each Leishmania species will
require a different drug combination. Suitable options for
combination treatment must therefore be optimised in further
experimental studies. In this respect, genome-sequencing and
metabolomics experiments are currently underway to determine
the specific resistance mechanisms developed by Leishmania
parasites to different drug combinations. Finally, in view of the
proven value of these results for the research community, and
considering the debate as regards the use of promastigotes or
intracellular amastigotes for induction of drug resistance to drug
combinations, we are currently attempting to induce resistance to
drug combinations in intracellular amastigotes, as the results
obtained will be of greater significance in terms of the conditions
found in the field.
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